TLSI · TriSalus Life Sciences, Inc. · Financials
$4.32
+0.17 (+4.10%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, strategic alliances and/or licensing arrangements to carry out our long-term business strategy. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. There can be no assurances that we will be successful in any of these respects, or that we will be able to continue to obtain outside capital in the future or do so on terms that are acceptable to us.”View the 10-Q filed Aug 6, 2026
Market Cap
$267.23M
Shares
61.57M
Volume · Oct 2
145.38K
Avg daily vol (3M)
287.52K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$45.15M
+53.4%
FY2025
Net Income
-$39.23M
-30.6%
FY2025
Gross Margin
84.57%
-1.5pp
FY2025
Operating Margin
-59.68%
+63.2pp
FY2025
Diluted EPS
-$1.84
-40.5%
FY2025
Operating Cash Flow
-$18.01M
+55.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|
| $54M – $57M | $45.08M | $45.15M | $29.43M | $18.51M | $12.4M | — | |
| — | $6.41M | $6.97M | $4.1M | $2.61M | $2.26M | — | |
| — | $38.67M | $38.19M | $25.33M | $15.91M | $10.14M | — | |
| — | — | 84.57% | 86.06% | 85.93% | 81.79% | — | |
| — | $14.63M | $14.97M | $17.69M | $29.84M | $21.36M | — | |
| — | $33.64M | $28.71M | $25.84M | $17.03M | $12.74M | — | |
| — | $20.91M | $21.46M | $17.97M | $23.51M | $12.48M | $3.04M | |
| — | — | — | — | $18K | $122K | — | |
| — | $560K | $626K | $744K | $684K | $398K | — | |
| — | -$30.51M | -$26.95M | -$36.17M | -$54.48M | -$36.44M | -$3.04M | |
| — | — | -59.68% | -122.88% | -294.28% | -293.91% | — | |
| — | -$29.95M | -$26.32M | -$35.42M | -$53.79M | -$36.04M | — | |
| — | $5.84M | $5.54M | $3.09M | $16K | $1000 | — | |
| — | $968K | $555K | $404K | $431K | $180K | $64K | |
| — | -$151K | -$456K | -$312K | -$378K | $8.86M | $7.81M | |
| — | -$28.2M | -$39.22M | -$30.04M | -$59.35M | -$47.18M | $4.77M | |
| — | $13K | $7000 | $6000 | $9000 | $9000 | $0 | |
| — | -$28.21M | -$39.23M | -$30.05M | -$59.36M | -$47.19M | $4.77M | |
| — | — | -86.88% | -102.09% | -320.69% | -380.6% | — | |
| — | -$57.25M | -$69.69M | -$33.23M | -$63.6M | -$50.02M | — | |
| USD/shares | — | -$1.31 | -$1.84 | -$1.31 | -$6.77 | -$161.55 | — |
| USD/shares | — | -$1.31 | -$1.84 | -$1.31 | -$6.77 | -$161.55 | — |
| shares | — | — | 37.9M | 25.33M | 9.4M | 309.61K | — |
| shares | — | — | 37.9M | 25.33M | 9.4M | 309.61K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Annual debt figures are established from annual reports and updated by subsequent interim reports and event disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Reported debt balances
Balances may overlap and are not added together. Each row keeps its reported scope and date.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent long-term debt | 2026-06-30 | USD 33,065,000 | 10-Q filed 2026-08-06 |
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.62×
EV/EBIT
—
Peer median 20.55×
P/E (TTM)
—
Peer median 24.75×
Peer medians compare against the 80 similar-size Medical Devices companies (of 150 listed).